FANCF methylation contributes to chemoselectivity in ovarian cancer

Cancer Cell. 2003 May;3(5):417-20. doi: 10.1016/s1535-6108(03)00111-9.


A new model of ovarian cancer tumor progression implicates aberrant FANCF promoter methylation that is associated with gene silencing and disruption of the Fanconi-anemia-BRCA pathway. Disruption of the pathway occurs de novo in ovarian cancers and may contribute to selective sensitivity to platinum salts.

Publication types

  • Review

MeSH terms

  • Alleles
  • BRCA1 Protein / genetics
  • DNA Methylation*
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Exons
  • Fanconi Anemia Complementation Group F Protein
  • Female
  • Humans
  • Models, Genetic
  • Oligonucleotide Array Sequence Analysis
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics*
  • Promoter Regions, Genetic
  • RNA-Binding Proteins / genetics*
  • Signal Transduction


  • BRCA1 Protein
  • FANCF protein, human
  • Fanconi Anemia Complementation Group F Protein
  • RNA-Binding Proteins